Lv11
90 积分 2022-08-24 加入
MM-547 MagnetisMM-32: Evaluation of Elranatamab vs EPd, PVd, or Kd in Patients With Relapsed or Refractory Multiple Myeloma and Prior Anti-CD38– Directed Therapy
2小时前
求助中
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
6个月前
已完结
Smoldering multiple myeloma current treatment algorithms
6个月前
已完结
[Research progress on the application of specially lense related to myopia prevention and control]
6个月前
已完结
Effect of da Vinci robot versus thoracoscopic surgery on lung function and oxidative stress levels in NSCLC patients: a propensity score-matched study
7个月前
已完结
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
7个月前
已完结
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
7个月前
已完结
Relapsed and refractory multiple myeloma: A systematic review and network meta‐analysis of the efficacy of novel therapies
7个月前
已完结
GPRC5D as a novel immunotherapeutic target in multiple myeloma
7个月前
已完结
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
8个月前
已完结
皖公网安备34019202002308
